A pilot study in patients with established advanced liver fibrosis using pirfenidone.
作者信息
Armendáriz-Borunda J, Islas-Carbajal M C, Meza-García E, Rincón A R, Lucano S, Sandoval A S, Salazar A, Berumen J, Alvarez A, Covarrubias A, Aréchiga G, García L
出版信息
Gut. 2006 Nov;55(11):1663-5. doi: 10.1136/gut.2006.107136.
Abstract
摘要
相似文献
1
A pilot study in patients with established advanced liver fibrosis using pirfenidone.一项在已确诊为晚期肝纤维化患者中使用吡非尼酮的试点研究。
Gut. 2006 Nov;55(11):1663-5. doi: 10.1136/gut.2006.107136.
2
Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.
Clin Exp Pharmacol Physiol. 2009 Oct;36(10):961-2. doi: 10.1111/j.1440-1681.2009.05262.x. Epub 2009 Jul 24.
3
Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.吡非尼酮通过防止肝星状细胞激活抑制四氯化碳和白蛋白复合物诱导的啮齿动物肝纤维化。
Clin Exp Pharmacol Physiol. 2009 Oct;36(10):963-8. doi: 10.1111/j.1440-1681.2009.05194.x. Epub 2009 Apr 27.
4
Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans.吡非尼酮在人体双盲临床预试验中的抗风湿作用
Res Commun Mol Pathol Pharmacol. 2004;115-116:39-48.
5
Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.慢性丙型肝炎合并桥接纤维化和代偿期肝硬化患者的门脉高压性胃病：来自HALT-C试验的结果
Am J Gastroenterol. 2006 May;101(5):983-92. doi: 10.1111/j.1572-0241.2006.00461.x.
6
Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.吡非尼酮：一种抗纤维化药物，在移植患者管理中具有潜在治疗作用。
Eur J Pharmacol. 2006 May 1;536(3):219-22. doi: 10.1016/j.ejphar.2006.03.007. Epub 2006 Mar 14.
7
Challenges in treating liver fibrosis.治疗肝纤维化的挑战。
Ann Hepatol. 2014 Nov-Dec;13(6):845-6.
8
Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.吡非尼酮：一种用于治疗慢性移植物排斥反应的新型潜在治疗药物。
Transplant Proc. 2007 Sep;39(7):2153-6. doi: 10.1016/j.transproceed.2007.07.078.
9
Clinical decisions in hepatology: the pirfenidone case analysis.
Ann Hepatol. 2014 Mar-Apr;13(2):163-5.
10
Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.特发性肺纤维化患者对吡非尼酮治疗的个体内反应。
Am J Respir Crit Care Med. 2015 Jan 1;191(1):110-3. doi: 10.1164/rccm.201406-1106LE.
引用本文的文献
1
Exploring the Therapeutic Potential of TGF-β Inhibitors for Liver Fibrosis: Targeting Multiple Signaling Pathways.探索TGF-β抑制剂对肝纤维化的治疗潜力：靶向多种信号通路
J Clin Transl Hepatol. 2025 Jul 28;13(7):588-598. doi: 10.14218/JCTH.2025.00029. Epub 2025 Jul 15.
2
Pharmacological Immunomodulation via Collagen-Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study.通过胶原蛋白-聚乙烯吡咯烷酮或吡非尼酮进行的药理免疫调节通过涉及JAK/STAT信号通路的相似作用机制在重症COVID-19患者的康复中发挥作用：一项初步研究。
Adv Respir Med. 2025 Jul 18;93(4):24. doi: 10.3390/arm93040024.
3
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective.机制导向的肝纤维化药物研发与治疗：临床视角
Front Pharmacol. 2025 May 26;16:1574385. doi: 10.3389/fphar.2025.1574385. eCollection 2025.
4
Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial.缓释吡非尼酮在代偿期肝硬化中的无创评估。ODISEA研究，一项随机试验。
Liver Int. 2025 Jun;45(6):e70131. doi: 10.1111/liv.70131.
5
H3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH.JMJD2B 通过 H3K9me3 去甲基化的调节作用被吡非尼酮所抑制，从而改善 NASH。
Sci Rep. 2024 Oct 21;14(1):24714. doi: 10.1038/s41598-024-75458-2.
6
Pirfenidone use in fibrotic diseases: What do we know so far?吡非尼酮在纤维性疾病中的应用：目前我们了解多少？
Immun Inflamm Dis. 2024 Jul;12(7):e1335. doi: 10.1002/iid3.1335.
7
Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice.吡非尼酮可预防无毛小鼠的 UVB 诱导的光损伤。
Molecules. 2023 Mar 24;28(7):2929. doi: 10.3390/molecules28072929.
8
New Drugs for Hepatic Fibrosis.治疗肝纤维化的新药。
Front Pharmacol. 2022 Jun 13;13:874408. doi: 10.3389/fphar.2022.874408. eCollection 2022.
9
Congenital hepatic fibrosis: case report and review of literature.先天性肝纤维化：病例报告及文献复习。
Pan Afr Med J. 2021 Feb 18;38:188. doi: 10.11604/pamj.2021.38.188.27941. eCollection 2021.
10
Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics.青蒿素及青蒿素衍生物作为抗纤维化治疗药物
Acta Pharm Sin B. 2021 Feb;11(2):322-339. doi: 10.1016/j.apsb.2020.09.001. Epub 2020 Sep 8.
本文引用的文献
1
Fibrosis in chronic liver diseases: diagnosis and management.慢性肝病中的纤维化：诊断与管理
J Hepatol. 2005;42 Suppl(1):S22-36. doi: 10.1016/j.jhep.2004.12.008. Epub 2004 Dec 24.
2
The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.
Dig Liver Dis. 2004 Nov;36(11):744-51. doi: 10.1016/j.dld.2004.05.012.
3
Pirfenidone effectively reverses experimental liver fibrosis.吡非尼酮可有效逆转实验性肝纤维化。
J Hepatol. 2002 Dec;37(6):797-805. doi: 10.1016/s0168-8278(02)00272-6.
4
Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference.肝纤维化的机制与治疗：美国肝病研究学会单主题基础研究会议报告
Hepatology. 2000 Dec;32(6):1403-8. doi: 10.1053/jhep.2000.20243.
5
Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.慢性丙型肝炎患者健康相关生活质量的降低及干扰素治疗后的改善。共识干扰素研究小组。
Hepatology. 1999 Jan;29(1):264-70. doi: 10.1002/hep.510290124.
Zotero 插件